Triple-Combination Therapy Met Primary End Point in Phase 3 Trials, Providing Treatment for Individuals With Asthma
A fixed-dose triple-combination therapy of budesonide, glycopyrronium, and formoterol fumarate (BGF, Breztri Aerosphere; AstraZeneca) met all primary end points in a phase 3 Kalos (NCT04609878) and Logos trial (NCT04609904) among individuals with uncontrolled asthma, demonstrating improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines.1 Image credit: Goffkein | stock.adobe.com The inhaled triple-combination … Read more